Andrew P. Lee

Array ( [id] => 17067239 [patent_doc_number] => 20210269454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => CYCLOALKANE-1,3-DIAMINE DERIVATIVE [patent_app_type] => utility [patent_app_number] => 17/243360 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198542 [patent_doc_number] => 20210338636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/235468 [patent_app_country] => US [patent_app_date] => 2021-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17235468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17143061 [patent_doc_number] => 20210311074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => METHOD FOR OBTAINING INFORMATION ON RISK OF REDUCED RESPIRATORY FUNCTION IN PATIENT WITH INTERSTITIAL PNEUMONIA [patent_app_type] => utility [patent_app_number] => 17/232397 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17232397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990302 [patent_doc_number] => 20210228722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/228025 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990140 [patent_doc_number] => 20210228560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol [patent_app_type] => utility [patent_app_number] => 17/222254 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17874300 [patent_doc_number] => 11446291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Methods for the treatment of abnormal involuntary movement disorders [patent_app_type] => utility [patent_app_number] => 17/212205 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 41777 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 207 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095304 [patent_doc_number] => 20210283095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => Detection and Treatment of Viral Diseases and Cancer [patent_app_type] => utility [patent_app_number] => 17/249734 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18311711 [patent_doc_number] => 20230115611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => TREATMENT OF PAIN AND VASOCONSTRICTION [patent_app_type] => utility [patent_app_number] => 17/802727 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -119 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18270094 [patent_doc_number] => 20230091336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => CANNABINOID COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/904934 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18298364 [patent_doc_number] => 20230108050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/800639 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17111751 [patent_doc_number] => 20210292348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => ANTIVIRAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/178115 [patent_app_country] => US [patent_app_date] => 2021-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17178115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854882 [patent_doc_number] => 20210155627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => KINASE INHIBITORS AND RELATED METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/165048 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18225333 [patent_doc_number] => 20230064327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/792208 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -174 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18225333 [patent_doc_number] => 20230064327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/792208 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -174 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18225333 [patent_doc_number] => 20230064327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/792208 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -174 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16837808 [patent_doc_number] => 20210145820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS [patent_app_type] => utility [patent_app_number] => 17/154312 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701437 [patent_doc_number] => 12195446 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Heteroaryl compounds and their use as therapeutic drugs [patent_app_type] => utility [patent_app_number] => 17/138309 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35688 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 555 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18148343 [patent_doc_number] => 20230022200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH [patent_app_type] => utility [patent_app_number] => 17/781778 [patent_app_country] => US [patent_app_date] => 2020-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16930839 [patent_doc_number] => 20210196728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => METHODS OF TREATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 17/130580 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913870 [patent_doc_number] => 20210186962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => METHODS OF SCHIZOPHRENIA TREATMENT [patent_app_type] => utility [patent_app_number] => 17/127867 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127867 [rel_patent_id] =>[rel_patent_doc_number] =>)